Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Expanding the donor pool was once again top of mind at the 2024 Cornea and Eye Banking Forum, held Oct. 18 in conjunction with the AAO meeting in Chicago, Illinois. The forum, supported by the Eye ...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...
Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...
Cure Blindness Project is expanding to six new countries—Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia, the charity reported Oct. 10. Paraguay marksthe charity’...
The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in September 2024, according to the agency’s database. Zeiss gained clearance for its combination Y...
Aurion Biotech announced Sept. 24 that it had launched Vyznova (neltependocel), a cell therapy for bullous keratopathy of the cornea, in Japan. Japanese regulators approved Vyznova in March 2023. T...
Farhad Hafezi, MD, PhD, FARVO (Switzerland), discussed at the 2024 ESCRS congress the goals of the second global consensus on keratoconus, being drafted in 2024. This consensus encompasses feedback...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Italy’s SIFI announced Sept. 30 the launch in Germany of its Akantior (polihexanide 0.08%) drops for the treatment of Acanthamoeba keratitis (AK), a parasitic infection of the eye, in patients 12 a...
Aurion Biotech announced Sept. 24 that it had launched Vyznova (neltependocel), a cell therapy for bullous keratopathy of the cornea, in Japan. Japanese regulators approved Vyznova in March 2023. T...
Italy’s SIFI announced Aug. 26 that the European Commission had approved Akantior (polihexanide 0.08%) drops for the treatment of Acanthamoeba keratitis (AK), a parasitic infection of the eye, in p...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
Japan’s Santen announced Aug. 6 that it had signed an agreement to license CBT-001, a topical pterygiumtreatment candidate from Cloudbreak Pharma. The deal covers the territories of Japan, South Ko...
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application (sNDA...
HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...
Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Eyenovia, of New York, announced July 23 that it had entered into a collaboration agreement with Japan’s Senju Pharmaceutical to develop Senju’s corneal epithelial wound healing candidate, SJP-0035...
Italy’s SIFI announced July 22 that a European advisory panel had recommended orphan drug designation for its polihexanide eye drop for fungal keratitis. The Committee for Orphan Medicinal Products...
Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...
Claes H. Dohlman, MD, PhD, considered by many to be the father of modern corneal science, died July 14, Massachusetts Eye and Ear announced in a press release. He was 101. Dohlman, who was born in ...
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Claes H. Dohlman, MD, PhD, considered by many to be the father of modern corneal science, died July 14, Massachusetts Eye and Ear announced in a press release. He was 101. Dohlman, who was born in ...
London’s Okyo Pharma announced July 11 that it would advance OK-101 into a Phase II clinical trial of neuropathic corneal pain (NCP). The US FDA cleared the investigational new drug (IND) applicati...
Johnson & Johnson is the lead investor in a Series A funding round for Stamford, Connecticut-based TecLens, developer of a new crosslinking technology, J&J announced June 21. The technology is inte...
Aurion Biotech announced June 19 that the US FDA had granted both breakthrough therapy and regenerative medicine advanced therapy status for AURN001, the company’s allogeneic cell therapy candidate...
Attendees at the 2024 Eye Banking Association of America (EBAA) meeting celebrated many achievements and milestones across the eye banking profession and transplant community in general, as 2023 ma...
Italy’s SIFI announced May 31 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of Akantior (polihexanide 0.08%) for the treatment...
Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...
BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...
Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...
BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...
Italy’s SIFI announced May 31 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of Akantior (polihexanide 0.08%) for the treatment...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...
Bausch + Lomb announced May 7 that it had launched the Zenlens Echo, a non-prosthetic, custom scleral contact lens, in the US. The company said the Echo is designed to fit a wide variety of corneal...
Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...
Descemet’s membrane endothelial keratoplasty (DMEK) has become the most common keratoplasty procedure performed domestically, according to a statistical report by the Eye Bank Association of Americ...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...
West Point Optical Group, which operates 86 Pearle Vision clinics in 13 states, announced April 3 that it had reached an agreement with Verséa Ophthalmics to offer Verséa’s Biovance and Biovance 3L...
ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...
Alcon announced March 26 that Terry Kim, MD, would join the company in April as chief medical officer (CMO) and head of global medical safety. Kim, who specializes in cornea, cataract, and refracti...
Design Therapeutics reported March 19 in its 2023 financial statement that the US FDA had cleared its investigational new drug (IND) application for a clinical trial of DT-168 in Fuchs’ endothelial...
Israel-based CorNeat Vision announced Feb. 27 that it had launched its EverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first syn...
Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...
Vital Tears announced March 6 that it had appointed Joseph Tauber, MD, as its chief medical officer. In 2023, Vital Tears added mobile phlebotomy services to its system of providing autologous seru...
Ireland-based Mallinckrodt announced March 1 that the US FDA had approved its supplemental new drug application (sNDA) for the H.P. Acthar Gel single-dose pre-filled SelfJect injector. SelfJect pro...
Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...
Israel-based CorNeat Vision announced Feb. 27 that it had launched itsEverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first synt...
Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...
Global nonprofit eye bank Eversight and Emmecell announced Feb. 20 that they would collaborate to advance cell therapies for corneal treatment. Emmecell, of Menlo Park, California, is developing EO...
Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...
A recent study by investigators at Mass Eye and Ear of the Harvard Medical School Department of Ophthalmology revealed that the neuropeptide α-melanocyte-stimulating hormone (α-MSH) promotes cornea...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
London’s Okyo Pharma announced Feb. 9 that the US FDA had cleared its investigational new drug (IND) application for topical candidate OK-101 in neuropathic corneal pain—a first for that indication...
Stuart Therapeutics, of Stuart, Florida, reported Feb. 1 that it had appointed Jodi Luchs, MD, as chief medical officer. Luchs is a board-certified, fellowship-trained ophthalmologist with a subspe...
Cornea treatment made a significant breakthrough in 2023, with the approval in Japan of Aurion Biotech’s novel cell therapy, Vyznova, for the treatment of bullous keratopathy. The milestone is a gl...
China’s Ji Xing Pharmaceuticals led recent ophthalmic fundraising efforts with $162 million in Series D funding to advance its pipeline, which includes five ophthalmic candidates. Financing announc...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...
A recent study by investigators at Mass Eye and Ear of the Harvard Medical School Department of Ophthalmology revealed that that administration of the neuropeptide α-melanocyte-stimulating hormone ...
Cellusion, of Tokyo, announced Dec. 22 that the US FDA had granted orphan drug designation to its induced pluripotent stem cell-derived corneal endothelial cell substitute, CLS001, for bullous kera...
KeraLink International, a nonprofit group focused on eradicating global corneal blindness, announced Dec. 11 that it had launched a Cornea Technology Accelerator, open to entrepreneurs and innovato...
EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Cornea Subspecialty Day has become the most popular pre-meeting event at the annual congress of the European Society of Cataract and Refractive Surgeons, with 629 attendees this year. Cornea specia...
Ukrainian ophthalmologists are struggling to restore sight to soldiers and confronting complex surgical cases, even as the Russian offensive continues in their country. A large contingent of 825 Uk...
Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...
NovaBay Pharmaceuticals and BioStem Technologies announced an agreement Sept. 11 under which NovaBay will commercialize BioStem’s ocular amniotic tissue allograft. No financial details for the deal...
Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Investigators at Cedars-Sinai in Los Angeles say they’ve identified diabetes-associated epigenetic changes to the cornea, providing a new understanding of how the disease delays wound healing in th...
Celularity and Verséa Ophthalmics announced an exclusive US commercial agreement on July 27. Verséa will distribute Celularity’s Biovance and Biovance 3L for ocular surface disease and ocular surgi...
Investigators at Cedars-Sinai in Los Angeles say they’ve identified diabetes-associated epigenetic changes to the cornea, providing a new understanding of how the disease delays wound healing in th...
Neurogene led recent ophthalmic fundraising efforts with a $95 million private placement, as it advances its pipeline, including a gene therapy candidate for Batten disease. Funding announced in th...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.